Machine Learning–Guided Identification of Stable mRNA Vaccine Sequence Designs

Background: Messenger RNA vaccines require precise sequence engineering to achieve optimal translational efficiency and molecular stability. Variations in nucleotide composition, secondary structure formation, and codon usage can significantly influence mRNA degradation rates and antigen expression. Computational approaches may assist in identifying sequence patterns that promote structural stability and improved translational performance. 

Methods: A dataset containing 4,320 synthetic mRNA constructs encoding viral antigen fragments was compiled from open molecular biology repositories. Each sequence was analysed for codon adaptation index, GC content, predicted secondary structure stability (ΔG), and untranslated region motif patterns. A gradient boosting machine-learning model was trained to predict sequence stability scores derived from simulated degradation kinetics. Model performance was evaluated using 10-fold cross-validation. Predictive accuracy was assessed using coefficient of determination (R²), mean absolute error (MAE), and root mean squared error (RMSE). 

Results: The final model achieved an R² of 0.88 for prediction of mRNA stability with an RMSE of 0.41 stability units and MAE of 0.32. Sequences with GC content between 48–56% demonstrated the highest predicted stability. Codon adaptation index values above 0.80 were associated with improved predicted translation efficiency. Feature importance analysis indicated that secondary structure energy contributed 34% of the predictive weight, followed by codon usage bias (27%) and untranslated region motif patterns (18%). Simulation experiments suggested that optimized sequence designs could increase predicted translational output by approximately 22%. 

Conclusion: Machine learning models can effectively identify sequence characteristics associated with improved mRNA stability and translation efficiency. Computational optimisation of mRNA vaccine constructs may reduce experimental screening efforts and support rapid design of next-generation vaccine candidates.

To be updated shortly..